Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7822755 | 0.92 | TACR1 (0.76) | TACR1 | |
| SCHEMBL8481191 | 0.92 | TACR1 (0.76) | TACR1 | |
| Hydrochloric Acid SCHEMBL7826655 | 0.91 | TACR1 (0.75) | TACR1 | |
| SCHEMBL7830997 | 0.91 | TACR1 (0.70) | TACR1 | |
| SCHEMBL7828222 | 0.90 | TACR1 (0.71) | TACR1 | |
| SCHEMBL7827040 | 0.90 | TACR1 (0.71) | TACR1 | |
| SCHEMBL8475617 | 0.90 | TACR1 (0.80) | TACR1 | |
| Hydrochloric Acid SCHEMBL8475494 | 0.90 | TACR1 (0.75) | TACR1 | |
| SCHEMBL8480834 | 0.90 | TACR1 (0.69) | TACR1 | |
| Hydrochloric Acid SCHEMBL7823925 | 0.90 | TACR1 (0.75) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
| EP-0655442-B1 | Piperazine derivatives as Tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-6087357-A | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| US-5883098-A | USED AS TACHYKININ ANTAGONISTS IN THE TREATMENT OF RESPIRATORY DISEASES, OPHTHALMIC DISEASES AND INFLAMMATORY DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-03-16 | — | — | US | disclosed |
| EP-0846116-A1 | 1-BENZOYL-2-(INDOLYL-3-ALKYL)-PIPERAZINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-10 | — | — | EP | disclosed |
| US-5670505-A | TACHYKIKIN ANTAGONIST FOR RESPIRATORY DISEASES, OPHTHALMIC DISEASES AND ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-23 | — | — | US | disclosed |
| WO-1996037489-A1 | 1-BENZOYL-2-(INDOLYL-3-ALKYL)-PIPERAZINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-11-28 | — | — | WO | disclosed |
| EP-0655442-A1 | Piperazine derivatives as Tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | PKD2, SSTR5, TAC3 | TACR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.